A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...

British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...

Peking University-led researchers have modified an existing treatment for liver disease that does not cause itchiness, a common side effect of existing treatments. Chronic itch is a debilitating ...

GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...

C7 alleviated liver injury and fibrosis in rodent studies without causing itching. Christa E. Müller, a scientist at the University of Bonn who studies the receptors that cause itch, says the ...

GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024PARIS, FRANCE, 18 ...

Ipsen announces Bylvay data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS: Paris, France Tuesday, November 19, 2024, 11:00 H ...